



## I. Epidemiological profile

Population (UN)	2016	%
Number of active foci	-	
Number of people living within active foci	0	0
Malaria-free (0 cases)	20,800,000	100
Total	20,800,000	

Parasites and vectors	
Plasmodium species:	<i>P. falciparum</i> (0%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. culicifacies</i> , <i>An. subpictus</i> , <i>An. annularis</i> , <i>An. varuna</i>
Reported confirmed cases (health facility):	0
Imported cases	41
Reported deaths:	0

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	1992
	ITNs/ LLINs distributed to all age groups	Yes	2004
IRS	IRS is recommended	Yes	1945
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	1911
Treatment	ACT is free of charge for all ages in public sector	Yes	2008
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2001
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2008
	G6PD test is a requirement before treatment with primaquine	Yes	2014
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring adverse reactions to antimalarials exists	Yes	2015
Surveillance	ACD for case investigation (reactive)	Yes	2011
	ACD of febrile cases at community level (pro-active)	Yes	2012
	Mass screening is undertaken	Yes	1997
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	2008
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	1958
	Case reporting from private sector is mandatory	Yes	2008

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	AL+PQ	2008
Treatment failure of <i>P. falciparum</i>	-	-
Treatment of severe malaria	QN	1936
Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2008
Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)
Type of RDT used		P.f + all species (Combo)


Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species

Insecticide resistance tests (mosquito mortality, %)							
Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
Carbamates	2010-2015	0	0.7	1	38	<i>An. culicifacies s.l.</i> , <i>An. subpictus s.l.</i> , + other	
Organochlorines	2010-2014	0	0.7	1	18	<i>An. culicifacies s.l.</i> , <i>An. subpictus s.l.</i> , + other	
Organophosphates	2010-2016	0	0.8	1	55	<i>An. culicifacies s.l.</i> , <i>An. subpictus s.l.</i> , + other	
Pyrethroids	2010-2016	0.2	1	1	119	<i>An. culicifacies s.l.</i> , <i>An. subpictus s.l.</i> , + other	





## III. Financing





## Government expenditure by intervention in 2016



## IV. Coverage



## V. Impact



**Notes:**  
Reported confirmed cases and reported deaths are indigenous only